Patients w/ bilateral renal artery, single kidney artery & aortic valve stenosis, & hypertrophic obstructive cardiomyopathy. Symptomatic hypotension may occur after initiation of therapy. Hepatic (consider dose reduction) & renal impairment. Hypotension in patients w/ vol-depletion (eg, under high-dose diuretic therapy). Hyperkalemia may occur; monitor serum K conc in elderly patients. Potential oliguria &/or progressive azotemia (less frequent) w/ acute renal failure &/or death in patients whose renal function may be renin-angiotensin-aldosterone-system-dependent (eg, patients w/ severe CHF).